• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IPD
Click for more information
3.39% 5.7¢

IMPEDIMED LIMITED - Corporate Spotlight

Market Cap $119.3M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Medical Devices

ImpediMed Limited is an Australia-based medical technology company. The Company uses... ImpediMed Limited is an Australia-based medical technology company. The Company uses bioimpedance spectroscopy (BIS) technology to generate data to maximize patient health. The Company designs and manufactures medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the noninvasive clinical assessment and monitoring of fluid status and tissue composition. The Company’s SOZO Digital Health Platform is a Food and Drug Administration (FDA)-cleared bioimpedance spectroscopy (BIS) solution for the clinical assessment of lymphedema. SOZO uses its BIS technology to measure and track critical information about the human body to aid clinicians in managing chronic disease and maximizing patient health. Its product SFB7 measures fluid status and tissue composition for clinical and research applications. Its ImpediVET is a single-channel, tetrapolar bioimpedance spectroscopy (BIS) device that measures fluid status and tissue composition for veterinary applications.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

No Corporate Spotlight currently available.

(20min delay)
Last
5.7¢ 		Change
-0.002(3.39%) 		Mkt cap ! $119.3M
Open High Low Value Volume
5.9¢ 5.9¢ 5.7¢ $4.054K 68.84K

Buyers (Bids)

No. Vol. Price($)
4 711122 5.7¢
 

Sellers (Offers)

Price($) Vol. No.
5.9¢ 145403 4
View Market Depth
Last trade - 11.39am 02/10/2024 (20 minute delay) ?
Last
5.9¢ 		  Change
-0.002 ( 3.15 %)
Open High Low Volume
5.9¢ 6.0¢ 5.7¢ 181517
Last updated 11.41am 02/10/2024 ?
IPD (ASX) Chart

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
PainChek close to finding out if FDA approves its flagship app for use in dementia care PainChek (ASX:PCK) has updated the market on the progress of its De Novo submission to the US FDA for its flagship app in aged care settings.
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Maximus jumps 7% as it unveils latest gold drill hits at Eagles Nest; grades up to 15g/t Maximus Resources (ASX:MXR) has unveiled its latest drilling assay results at Eagles Nest, hitting gold downhole multiple assets.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.